Macquarie Group
MGX icon

Macquarie Group’s Metagenomi Therapeutics MGX Stock Holding History

Macquarie Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-355
Closed -$4 – 2170
2024
Q1 		$4 Buy
+355
New +$4.08K ﹤0.01% 1826

Other funds holding MGX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group's MGX Position: Q2 2024 in Review

Macquarie Group sold out of Metagenomi Therapeutics (MGX) in Q2 2024, closing a stake of 355 shares — an estimated $4 sold.

Macquarie Group first reported a position in MGX in Q1 2024 and held it in 1 quarter. The position peaked at $4 in Q1 2024. 54 funds tracked by Wall St. Rank hold MGX as of Q2 2024.

  • Macquarie Group reported no remaining Metagenomi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 355 Metagenomi Therapeutics shares in Q2 2024, an estimated $4.
  • Macquarie Group first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Metagenomi Therapeutics position peaked at $4 in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.